Results 241 to 250 of about 2,820,603 (281)
Alpha-1 Antitrypsin Augmentation Therapy
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013 The therapy of alpha-1 antitrypsin deficiency (AATD) is an example of a medical triumph over a common hereditary disease. Based on the understanding of the pathogens of the disease as a deficiency in liver production of alpha-1 antitrypsin (AAT) resulting from inherited genetic variation in both parental AAT genes, the knowledge that A1AT functions ...
Ronald Crystal, Mark D Wewers
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Buspirone Augmentation of Antidepressant Therapy
Journal of Clinical Psychopharmacology, 1998Thirty outpatients meeting DSM-III-R or DSM-IV criteria for major depression, single or recurrent episode, and failing to respond to an adequate trial of an antidepressant (>6 weeks at recommended dosage) received buspirone (20-30 mg/day) for 4 or 5 weeks in addition to their existing antidepressant.
E C, Dimitriou, C E, Dimitriou
openaire +2 more sources
Quantitative Assessment of Augmentation Therapy
The Journal of Dermatologic Surgery and Oncology, 1990Abstract. We report the results obtained from 18 women whose facial folds and furrows were treated with augmentation therapy. The results of treatment with microlipoinjection and injectable collagen were measured and compared at regular intervals for a period of 1 year using a method of optical profilometry.
D E, Gormley, S, Eremia
openaire +2 more sources
Augmentation Strategies in Electroconvulsive Therapy
The Journal of ECT, 2010Electroconvulsive therapy (ECT) is a highly effective treatment, but strategies to enhance therapeutic outcomes are occasionally needed. This review examines the evidence for approaches used for enhancing seizure production: hyperventilation, pretreatment with xanthines, and use of remifentanil or ketamine in ECT anesthesia.
Colleen, Loo +2 more
openaire +2 more sources
A.M.A. Archives of Internal Medicine, 1959
William Withering, in 1785, stated, in referring to digitalis: "Let the medicine therefore be given in the dose and at the intervals mentioned above:—let it be continued until it either acts on the kidneys, the stomach, the pulse, or the bowels; let it be stopped upon the first appearance of any of these effects." 1 Since that time, however, it has ...
E H, BLACKARD, T R, HARRISON
openaire +2 more sources
William Withering, in 1785, stated, in referring to digitalis: "Let the medicine therefore be given in the dose and at the intervals mentioned above:—let it be continued until it either acts on the kidneys, the stomach, the pulse, or the bowels; let it be stopped upon the first appearance of any of these effects." 1 Since that time, however, it has ...
E H, BLACKARD, T R, HARRISON
openaire +2 more sources
Spiritually Augmented Cognitive Behavioural Therapy
Australasian Psychiatry, 2004Objective: To describe spiritually augmented cognitive behaviour therapy (SACBT) and its applications. Methods: The background for the need to incorporate spirituality into therapy is considered, and SACBT as a therapy for sustaining mental health and functional recovery is described. Cognitive and behavioural components are considered, including the
Russell F, D'Souza, Angelo, Rodrigo
openaire +2 more sources
Micro/Nanomaterials‐Augmented Hydrogen Therapy
Advanced Healthcare Materials, 2019AbstractHydrogen therapy is an emerging and promising therapy strategy of using molecular hydrogen as a new type of safe and effective therapeutic agent, exhibiting remarkable therapeutic effects on many oxidative stress‐/inflammation‐related diseases owing to its bio‐reductivity and homeostatic regulation ability.
Gaoxin Zhou, Ekta Goshi, Qianjun He
openaire +2 more sources
Current Medical Research and Opinion, 2018 Aims: Augmentation therapy is an option for patients with major depressive disorder who do respond sufficiently to adequate dosages of selective serotonin reuptake inhibitors or serotonin–norepinephrine reuptake inhibitors, but little is known about ...
Kunitoshi Kamijima
exaly +2 more sources
Gabapentin augmentation therapy in bipolar depression
Bipolar Disorders, 2002Background: Gabapentin (GBP) may be useful in bipolar disorders, including as adjunctive therapy for bipolar depression, although controlled studies suggest inefficacy as primary treatment for mania or treatment‐resistant rapid cycling.Methods: We performed a 12‐week trial of open GBP (mean dose 1725 mg/day) added to stable doses of mood stabilizers ...
Po W, Wang +5 more
openaire +2 more sources
Augmentation of standard depression therapy
Clinical Therapeutics, 2000This article reviews treatment options (eg, augmentation) for depressed patients with suboptimal clinical responses to an antidepressant.Approximately one third of patients treated with antidepressants exhibit suboptimal or delayed clinical response to these medications.
openaire +2 more sources